Display options
Cite
Chen PM, Gregersen H, Zhao JB. Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats. World J Diabetes. 2015;6(4):662-72doi: 10.4239/wjd.v6.i4.662.
Chen, P. M., Gregersen, H., & Zhao, J. B. (2015). Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats. World journal of diabetes, 6(4), 662-72. https://doi.org/10.4239/wjd.v6.i4.662
Chen, Peng-Min, et al. "Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats." World journal of diabetes vol. 6,4 (2015): 662-72. doi: https://doi.org/10.4239/wjd.v6.i4.662
Chen PM, Gregersen H, Zhao JB. Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats. World J Diabetes. 2015 May 15;6(4):662-72. doi: 10.4239/wjd.v6.i4.662. PMID: 25987965; PMCID: PMC4434088.
Copy Download .nbib Format: NLM
Share it on

World J Diabetes. 2015 May 15;6(4):662-72. doi: 10.4239/wjd.v6.i4.662.

Advanced glycation end-product expression is upregulated in the gastrointestinal tract of type 2 diabetic rats.

World journal of diabetes

Peng-Min Chen, Hans Gregersen, Jing-Bo Zhao

Affiliations

  1. Peng-Min Chen, Department of Molecular Biology, Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing 100029, China.

PMID: 25987965 PMCID: PMC4434088 DOI: 10.4239/wjd.v6.i4.662

Abstract

AIM: To investigate changes in advanced glycation end products (AGEs) and their receptor (RAGE) expression in the gastrointestinal (GI) tract in type 2 diabetic rats.

METHODS: Eight inherited type 2 diabetic rats Goto-Kakizak (GK) and ten age-matched normal rats were used in the study. From 18 wk of age, the body weight and blood glucose were measured every week and 2 wk respectively. When the rats reached 32 wk, two-centimeter segments of esophagus, duodenum, jejunum, ileum, and colon were excised and the wet weight was measured. The segments were fixed in 10% formalin, embedded in paraffin and five micron sections were cut. The layer thickness was measured in Hematoxylin and Eosin-stained slides. AGE [N epsilon-(carboxymethyl) lysine and N epsilon-(carboxyethyl)lysine] and RAGE were detected by immunohistochemistry staining and image analysis was done using Sigmascan Pro 4.0 image analysis software.

RESULTS: The blood glucose concentration (mmol/L) at 18 wk age was highest in the GK group (8.88 ± 1.87 vs 6.90 ± 0.43, P < 0.001), a difference that continued to exist until the end of the experiment. The wet weight per unit length (mg/cm) increased in esophagus, jejunum and colon from the normal to the GK group (60.64 ± 9.96 vs 68.56 ± 11.69, P < 0.05 for esophagus; 87.01 ± 9.35 vs 105.29 ± 15.45, P < 0.01 for jejunum; 91.37 ± 7.25 vs 97.28 ± 10.90, P < 0.05 for colon). Histologically, the layer thickness of the GI tract was higher for esophagus, jejunum and colon in the GK group [full thickness (μm): 575.37 ± 69.22 vs 753.20 ± 150.41, P < 0.01 for esophagus; 813.51 ± 44.44 vs 884.81 ± 45.31, P < 0.05 for jejunum; 467.12 ± 65.92 vs 572.26 ± 93.60, P < 0.05 for colon]. In esophagus, the AGE and RAGE mainly distributed in striated muscle cells and squamous epithelial cells. The AGE distribution was much stronger in the GK group compared to the normal group both in the striated muscle layer and mucosa layer (immuno-positive area/ total measuring area %: 4.52 ± 0.89 vs 10.96 ± 1.34, P < 0.01 for muscle; 8.90 ± 2.62 vs 22.45 ± 1.26, P < 0.01 for mucosa). No visible difference was found for RAGE distribution between the two groups. In the intestine AGE and RAGE distributed in epithelial cells of villi and crypt. RAGE was also found in neurons in the myenteric and submucosal plexus. The intensity of AGE staining in mucosa of all segments and RAGE staining in neurons in all segments were strongest in the diabetes group. Significant difference for AGE was found in the epithelial cells of villi and crypt in duodenum (immuno-positive area/total measuring area %: 13.37 ± 3.51 vs 37.48 ± 8.43, P < 0.05 for villi; 0.38 ± 0.12 vs 1.87 ± 0.53, P < 0.05 for crypt) and for RAGE in neurons of all segments (e.g., for jejunum: no staining neurons% 0 vs 0, mild 36.0 ± 5.2 vs 28.7 ± 3.5, moderate 53.2 ± 4.8 vs 55.8 ± 5.4, strong 10.7 ± 1.1 vs 15.4 ± 2.0, P < 0.05). In the colon, RAGE was primarily found in neurons in the myenteric and submucosal plexus. It was stronger in the diabetes group than in the normal group (no staining neurons% 6.2 ± 0.2 vs 0.3 ± 0.04, mild 14.9 ± 2.1 vs 17.6 ± 1.5, moderate 53.1 ± 4.6 vs 44.7 ± 4.4, strong 25.6 ± 18 vs 43.6 ± 4.0, P < 0.05). In the rectum, RAGE was primarily found in the mucosa epithelial cells.

CONCLUSION: The AGE and RAGE expression was up-regulated in the GI tract of GK diabetic rats and may contribute to GI dysfunction in type 2 diabetic patients.

Keywords: Advanced glycation end products; Diabetes mellitus; Gastrointestinal complications; Receptor of advanced glycation end products

References

  1. Biorheology. 2009;46(1):63-72 - PubMed
  2. Microvasc Res. 2011 May;81(3):269-73 - PubMed
  3. Dig Dis Sci. 2009 Aug;54(8):1636-42 - PubMed
  4. Graefes Arch Clin Exp Ophthalmol. 2003 Mar;241(3):213-25 - PubMed
  5. Eur J Heart Fail. 2009 Jul;11(7):638-47 - PubMed
  6. Dig Dis Sci. 2012 Jan;57(1):48-57 - PubMed
  7. J Clin Invest. 1977 Jul;60(1):181-8 - PubMed
  8. Korean J Intern Med. 2009 Dec;24(4):309-17 - PubMed
  9. Diabetologia. 1996 Aug;39(8):946-51 - PubMed
  10. J Gastroenterol. 2006 Nov;41(11):1076-87 - PubMed
  11. World J Gastroenterol. 2006 May 14;12(18):2846-57 - PubMed
  12. Neurogastroenterol Motil. 2008 Jul;20(7):818-28 - PubMed
  13. Am J Physiol. 1997 Oct;273(4 Pt 1):E815-20 - PubMed
  14. Neurogastroenterol Motil. 2008 Mar;20(3):253-61 - PubMed
  15. Gut. 1999 Jan;44(1):72-6 - PubMed
  16. J Nippon Med Sch. 2001 Dec;68(6):472-81 - PubMed
  17. J Nucl Med. 2010 Jan;51(1):92-7 - PubMed
  18. Mol Cell Biochem. 2003 Oct;252(1-2):125-32 - PubMed
  19. World J Gastroenterol. 2010 Apr 14;16(14):1782-7 - PubMed
  20. J Clin Invest. 2001 Dec;108(12):1853-63 - PubMed
  21. Curr Mol Med. 2007 Dec;7(8):766-76 - PubMed
  22. Curr Diab Rep. 2006 Dec;6(6):417-23 - PubMed
  23. Ann N Y Acad Sci. 2005 Jun;1043:598-604 - PubMed
  24. Diabetologia. 2004 Feb;47(2):331-9 - PubMed
  25. World J Cardiol. 2012 Apr 26;4(4):90-102 - PubMed
  26. Diabetes. 1996 Jul;45 Suppl 3:S67-72 - PubMed
  27. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4630-4 - PubMed
  28. Vasc Med. 2006 Nov;11(4):245-50 - PubMed
  29. Lab Invest. 2001 Jun;81(6):845-61 - PubMed
  30. Biochemistry. 1996 Jun 18;35(24):8075-83 - PubMed
  31. Curr Pharm Des. 2008;14(10):946-52 - PubMed
  32. Neurogastroenterol Motil. 2006 May;18(5):392-400 - PubMed
  33. J Diabetes Complications. 2007 Jan-Feb;21(1):34-40 - PubMed
  34. Kidney Int. 2004 Dec;66(6):2137-47 - PubMed
  35. Diabetes Res Clin Pract. 2007 Feb;75(2):127-34 - PubMed
  36. Comp Biochem Physiol A Comp Physiol. 1985;82(1):83-9 - PubMed
  37. Digestion. 2003;68(2-3):102-8 - PubMed
  38. J Mol Med (Berl). 2005 Nov;83(11):876-86 - PubMed
  39. J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S35-42 - PubMed
  40. J Cell Biochem. 2005 May 15;95(2):281-92 - PubMed
  41. Exp Eye Res. 2007 Sep;85(3):406-12 - PubMed
  42. Metabolism. 2003 Dec;52(12):1558-63 - PubMed
  43. Diabetologia. 2003 Dec;46(12):1688-97 - PubMed
  44. J Biol Chem. 2002 Mar 1;277(9):6888-97 - PubMed

Publication Types